Live Feeds
● TRACKER Updated 15d ago Β· 37 sources tracked

Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.

Viking Therapeutics secured $575 million to fund late-stage obesity drug trials, pipeline development, and commercial preparation for its VK2735 treatment. The funding follows trial data revealing that patients switching to less frequent dosing maintained significant weight reduction. Individuals receiving injections every other week retained about 97% of their average weight reduction, while monthly dosing patients maintained roughly 90%. That performance surpassed the 61% retention rate seen in placebo switchers, driving market enthusiasm while competitors Eli Lilly and Novo Nordisk experienced declines.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (37)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ Viking Therapeutics raised $575 million to fund major obesity drug trials, pipeline development, and commercial development for VK2735.
  • βœ“ Weekly dosing during the first 21 weeks of the trial produced weight loss of 16% to 19% compared with roughly 0% for placebo.
  • βœ“ Patients switching to injections every other week retained about 97% of their average weight reduction.
  • βœ“ Patients on monthly dosing maintained roughly 90% of their weight loss, compared with 61% for those switched to placebo.
πŸ›‘οΈ Source Corroboration: 37 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Viking Therapeutics raised $575 million and released trial data showing patients could maintain weight loss on less frequent dosing intervals.

Live updates

  1. Viking Therapeutics Raises $575M Following Trial Results

    Viking Therapeutics secured $575 million to fund late-stage obesity drug trials, pipeline development, and commercial preparation for its VK2735 treatment. The funding follows trial data revealing that patients switching to less frequent dosing maintained significant weight reduction. Individuals receiving injections every other week retained about 97% of their average weight reduction, while monthly dosing patients maintained roughly 90%. That performance surpassed the 61% retention rate seen in placebo switchers, driving market enthusiasm while competitors Eli Lilly and Novo Nordisk experienced declines.

    Why it matters

    Most existing weight-loss medications require weekly compliance, prompting intense market interest in whether Viking could sustain results with reduced injection frequency. The company advanced its oral formulation of VK2735 into phase III trials while simultaneously exploring weight maintenance strategies. These developments position Viking to challenge established market leaders in the lucrative obesity treatment sector.

    What is confirmed

    • Viking Therapeutics raised $575 million to fund major obesity drug trials, pipeline development, and commercial development for VK2735.
    • Weekly dosing during the first 21 weeks of the trial produced weight loss of 16% to 19% compared with roughly 0% for placebo.
    • Patients switching to injections every other week retained about 97% of their average weight reduction.
    • Patients on monthly dosing maintained roughly 90% of their weight loss, compared with 61% for those switched to placebo.

    Still unconfirmed

    • Eli Lilly and Novo Nordisk fell as a result of Viking Therapeutics raising $575 million and releasing trial data.

    What to watch next

    • Further progress and results from the phase III trials for oral and injectable VK2735
    • Updates on commercial development and regulatory approvals for the drug pipeline
    Sources used for this update (5)
    1. finance.yahoo.com β€” Viking Therapeutics Just Raised $575 Million. Here's What It ...
    2. finance.yahoo.com β€” Can Viking Therapeutics Carve Out a Place in the Obesity Market?
    3. vistapglobal.com β€” Viking Therapeutics Stock and Its Obesity Drug Future - Vista ...
    4. www.risingstarstocks.com β€” Viking’s Obesity Drug Can Work on a Monthly Schedule
    5. www.feedzop.com β€” Viking Therapeutics Raises $575M for Obesity Drug Trials
    confidence 95%

  2. Viking Therapeutics Initiates Phase 3 Oral Trials for Obesity Drug

    Viking Therapeutics initiated two Phase 3 clinical trials for its once-daily oral weight-loss treatment, VK2735. The SUNRISE-1 and SUNRISE-2 studies evaluate the dual GLP-1 and GIP receptor agonist in obese adults with and without type 2 diabetes. This late-stage push positions the company to compete against market leaders Eli Lilly and Novo Nordisk. Previous clinical results for the experimental pill showed a mean weight loss of up to 12.2 percent. The company's expanding pipeline also includes subcutaneous trials and ongoing exploratory maintenance dosing studies.

    Why it matters

    The launch of the Phase 3 SUNRISE program represents a major step for Viking Therapeutics in the competitive weight-loss drug market. The oral pill builds on earlier phase results and expands the company's clinical footprint alongside its ongoing VANQUISH trials. Management previously secured funding through a US$225 million convertible note offering and a US$275.0 million follow-on equity sale to support these programs.

    What is confirmed

    • Viking Therapeutics launched two Phase 3 trials of once-daily oral VK2735, a dual GLP-1 and GIP receptor agonist, in adults with obesity, with and without type 2 diabetes.
    • The SUNRISE-1 and SUNRISE-2 studies evaluate oral VK2735 in obese adults with and without type 2 diabetes.
    • Phase 2 results for oral VK2735 showed up to 12.2% mean weight loss.

    What to watch next

    • Results from the SUNRISE-1 and SUNRISE-2 Phase 3 clinical trials
    • Additional oral and subcutaneous dosing regimens, including monthly and every-other-week options, planned by the end of 2026
    Sources used for this update (7)
    1. ir.vikingtherapeutics.com β€” Viking Therapeutics Announces Initiation of VK2735 Oral Phase ...
    2. finance.yahoo.com β€” Viking Therapeutics Starts Phase III Development of Obesity Pill
    3. www.zacks.com β€” Viking Therapeutics Starts Phase III Development of Obesity ...
    4. www.biopharminternational.com β€” Viking Starts Phase 3 SUNRISE Program for Oral VK2735 in Obesity
    5. stocktwits.com β€” Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What ...
    6. www.prnewswire.com β€” Viking Therapeutics Announces Initiation of VK2735 Oral Phase ...
    7. markets.ft.com β€” Viking Therapeutics Announces Initiation of VK2735 Oral Phase ...
    confidence 100%

  3. Viking Advances VK2735 Oral Trial and Capital Raises

    Viking Therapeutics launched an exploratory oral maintenance dosing trial for its obesity drug candidate VK2735 involving about 195 adults taking tablets after 21 weeks of initial subcutaneous injections through week 33. The company also advanced its Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials, reporting both studies are fully enrolled. To support these expanding programs, Viking completed a US$225 million convertible note offering and a US$275.0 million follow-on equity sale following positive top-line maintenance data. Management plans to test additional oral and subcutaneous dosing regimens, including monthly and every-other-week options, by the end of 2026.

    Why it matters

    Viking's stock previously surged following clinical trial results showing substantial weight loss and strong weight maintenance with the GLP-1 and GIP agonist. The fresh capital injection gives the company funding flexibility to run larger trials and expand its metabolic disorder pipeline without depending solely on existing cash. These developments unfold alongside aggressive competition in the obesity drug market from major players such as Eli Lilly and Novo Nordisk.

    What is confirmed

    • Viking Therapeutics started an exploratory oral maintenance dosing study of obesity drug candidate VK2735 in about 195 adults testing tablets after 21 weeks of injections through week 33.
    • Both Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials of VK2735 are now fully enrolled.
    • Viking Therapeutics completed a US$225 million convertible note offering and a US$275.0 million follow-on equity sale.

    What to watch next

    • Results from the oral formulation testing planned by year-end 2026
    • Progress and data readouts from the Phase 3 VANQUISH-1 and VANQUISH-2 trials
    Sources used for this update (8)
    1. ir.vikingtherapeutics.com β€” Viking Therapeutics Announces Initiation of VK2735 Oral ...
    2. www.biospace.com β€” Significant stock movers of September: Viking soars ...
    3. simplywall.st β€” Weight Loss Maintenance Data Could Be A Big Test For Viking ...
    4. www.clinicaltrialvanguard.com β€” Viking Therapeutics Advances VK2735 Oral Program Into Phase 3 ...
    5. www.biospace.com β€” Obesity - BioSpace
    6. mugglehead.com β€” Viking Therapeutics begins VK2735 maintenance study
    7. simplywall.st β€” What Does Viking Therapeutics (VKTX) New VK2735 Trial Update ...
    8. finance.yahoo.com β€” VKTX Advances Obesity Program With New Oral Maintenance Study
    confidence 100%

  4. Viking Therapeutics Shares Surge on Obesity Drug Data

    Viking Therapeutics shares rose 36% following positive clinical trial results for its obesity drug VK2735. Patients achieved 16% to 19% weight loss over 21 weeks. Maintenance data for the GLP-1 and GIP agonist showed patients retained between 85% and 97% of their weight loss with once-a-month dosing. Meanwhile, Eli Lilly reported mid-stage data for EloraTZP, a combination of eloralintide and tirzepatide, which produced greater weight loss than tirzepatide alone, increasing competitive pressure on Novo Nordisk. Simultaneously, competitors Eli Lilly and Novo Nordisk saw their shares fall as the market reacted to the new obesity drug developments and trial data.

    Why it matters

    The obesity drug market is seeing intense competition between major pharmaceutical players following successful trial readouts. New combination therapies and dosing schedules are shifting investor expectations across the pharmaceutical sector. This dynamic directly impacts market valuations for leading drug developers.

    What is confirmed

    • Viking Therapeutics shares rose 36% after positive clinical trial results for its obesity drug VK2735.
    • Patients achieved 16% to 19% weight loss over 21 weeks on VK2735.
    • Maintenance data showed patients retained between 85% and 97% of their weight loss with once-a-month dosing.
    • Eli Lilly reported mid-stage data for EloraTZP, a combination of eloralintide and tirzepatide.

    What to watch next

    • Further clinical trial results for VK2735 and EloraTZP
    • Market share shifts between Viking Therapeutics, Eli Lilly, and Novo Nordisk
    Sources used for this update (4)
    1. en.wikipedia.org β€” Vikings - Wikipedia
    2. en.wikipedia.org β€” Viking Age - Wikipedia
    3. www.history.com β€” Vikings | HISTORY , Origins & Tactics | HISTORY
    4. www.vikinggroupinc.com β€” Viking Group Inc.
    confidence 100%

  5. Viking Therapeutics Shares Jump 36% on VK2735 Weight-Loss Data

    Viking Therapeutics shares rose 36% after positive clinical trial results for its obesity drug VK2735. Patients achieved 16% to 19% weight loss over 21 weeks. Maintenance data for the GLP-1 and GIP agonist showed patients retained between 85% and 97% of their weight loss with once-a-month dosing. Simultaneously, Eli Lilly reported mid-stage data for EloraTZP, a combination of eloralintide and tirzepatide, which produced greater weight loss than tirzepatide alone, increasing competitive pressure on Novo Nordisk.

    Why it matters

    The obesity market is shifting toward long-term maintenance and combination therapies to improve efficacy. Viking's monthly dosing targets patient convenience, while Lilly's new combination drug aims to outperform current industry standards.

    What is confirmed

    • Viking Therapeutics shares surged 36% following positive clinical results.
    • VK2735 demonstrated weight loss of 16% to 19% in patients over 21 weeks.

    Still unconfirmed

    • EloraTZP delivered greater weight loss than tirzepatide alone.

    What to watch next

    • Further clinical trial data for EloraTZP
    • Additional catalyst announcements from Viking Therapeutics within 18 months
    Sources used for this update (4)
    1. www.fool.com β€” Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
    2. finance.biggo.com β€” Viking's Once-Monthly Obesity Maintenance Therapy Succeeds ...
    3. finance.yahoo.com β€” Eli Lilly obesity drug data adds pressure on Novo Nordisk
    4. dyax.io β€” Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data ...
    confidence 85%

  6. Viking Surges on Monthly Dosing Data as Obesity Drug Race Heats Up

    Viking Therapeutics shares jumped up to 36% following positive topline results from a maintenance study of its GLP-1 and GIP agonist, VK2735. The treatment demonstrated strong weight-loss retention with once-a-month dosing, allowing patients to maintain 90 to 97 percent of their weight loss. Meanwhile, Eli Lilly captured approximately 7 in 10 of the roughly 700,000 seniors who began taking GLP-1 medications after Medicare coverage started on July 1. Eli Lilly also impressed observers with combination data for amylin and Zepbound at a European obesity scientific meeting.

    Why it matters

    The anti-obesity drug market continues to expand rapidly as companies race to capture market share through innovative delivery methods and combination therapies. Maintenance studies are critical for proving whether patients can sustain weight loss over time without burdensome weekly injections. At the same time, newly initiated Medicare coverage has opened a massive demographic of seniors to GLP-1 treatments, significantly shifting early adoption numbers toward market leaders.

    What is confirmed

    • Viking Therapeutics shares surged up to 36% following positive topline maintenance results for its GLP-1 and GIP agonist, VK2735.
    • VK2735 demonstrated strong weight-loss retention with once-a-month dosing regimens, showing patients can maintain 90-97% weight loss.
    • Eli Lilly captured about 7 in 10 of the roughly 700,000 seniors who have started GLP-1s since Medicare coverage began on July 1.

    Still unconfirmed

    • Eli Lilly is a safer buy while Viking Therapeutics is better suited for aggressive investors.

    What to watch next

    • Further clinical data releases regarding VK2735 and monthly dosing regimens
    • Adoption and prescription trends among Medicare seniors utilizing GLP-1 treatments
    • Progress from competitor pipelines including Novo, AbbVie, and Boehringer
    Sources used for this update (6)
    1. www.matterfact.com β€” Viking Soars, Novo Stumbles, Medicare Seniors Pile Into Lilly ...
    2. www.matterfact.com β€” Viking's Monthly Dose Data Jolts the Obesity Race as Novo ...
    3. www.fool.com β€” Eli Lilly Stock Barely Moved Following Viking Therapeutics ...
    4. bobby.ai β€” LLY vs VKTX: Weight Loss Drug Battle Heats Up | Bobby
    5. www.fool.com β€” 3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial ...
    6. www.biopharmadive.com β€” 3 takeaways from a European obesity scientific meeting | BioPharma Dive
    confidence 90%

  7. Viking Therapeutics skyrockets on obesity drug data, rivals fall

    Viking Therapeutics' shares surged up to 36% following positive topline results from a maintenance study of its GLP-1/GIP agonist, VK2735, demonstrating strong weight-loss retention with once-a-month dosing regimens. The stock remains above a key support level of $32.11 despite a minor slip of 1.86%. VK2735 showed patients can maintain 90-97% weight loss on monthly injections.

    Why it matters

    The obesity drug market is highly competitive, with major players like Eli Lilly and Novo Nordisk. Viking Therapeutics' VK2735 has shown promising results, potentially rivaling big pharma companies. The company's flexible dosing results could carve out real market share in the obesity drug race.

    What is confirmed

    • VK2735 demonstrated strong weight-loss retention with once-a-month dosing regimens.
    • Patients on VK2735 can maintain 90-97% weight loss on monthly injections.
    • Viking Therapeutics' shares rose up to 36% following positive topline results.
    • The treatment achieved 22% more weight loss than a placebo by week 33.

    Still unconfirmed

    • Switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.

    What to watch next

    • Upcoming clinical trial results from Eli Lilly and Novo Nordisk
    • FDA approval decisions for VK2735 and competing obesity drugs
    • Market share dynamics in the obesity drug market
    Sources used for this update (9)
    1. finance.yahoo.com β€” Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
    2. timetrending.com β€” λΉ„ν‚Ή ν…ŒλΌν“¨ν‹±μŠ€, λΉ„λ§Œ 치료제 데이터에 폭등…일라이 릴리, 노보 λ…Έλ””μŠ€ν¬λŠ” ....
    3. finance.yahoo.com β€” Obesity titan could shake up Lilly and Novo after astonishing ...
    4. www.thedailyupside.com β€” Viking Therapeutics Soars as Weight-Loss Drug Trial Addresses ...
    5. www.marketbeat.com β€” VKTX News Today | Why did Viking Therapeutics stock go down today?
    6. finance.yahoo.com β€” VKTX Stock On Track To Beat LLY, NVO This Month After Obesity ...
    7. www.bioreview.com β€” Viking VK2735 Maintenance Data: The Obesity Drug Market's ...
    8. www.ibtimes.com.au β€” Viking Therapeutics Shares Soar 30% as Obesity Drug Trial ...
    9. www.alphapilot.tech β€” Viking Therapeutics Stock Surges 40% as VK2735 Data Show ...
    confidence 85%

  8. Viking Therapeutics Stock Surges on VK2735 Weight-Loss Maintenance Data

    Viking Therapeutics shares rose up to 36% following positive topline results from a maintenance study of its GLP-1/GIP agonist, VK2735. The drug demonstrated strong weight-loss retention with once-a-month dosing regimens. Market reaction saw Viking stock skyrocket while competitors Eli Lilly and Novo Nordisk declined. One report indicates the treatment achieved 22% more weight loss than a placebo by week 33 without reaching a plateau. Recent trading data shows the stock holding above a key support level of $32.11 despite a minor slip of 1.86%.

    Why it matters

    VK2735 competes in the high-growth obesity market against established GLP-1 therapies. The ability to maintain weight loss with monthly dosing could reduce patient burden and increase competitiveness. This data tests the long-term efficacy of Viking's candidate compared to existing industry leaders.

    What is confirmed

    • Viking Therapeutics stock surged up to 36% following weight-loss drug trial data.
    • The maintenance study for GLP-1/GIP agonist VK2735 showed positive topline results.
    • VK2735 demonstrates weight-loss retention using monthly dosing.
    • Shares of Eli Lilly and Novo Nordisk fell as Viking Therapeutics stock rose.

    Still unconfirmed

    • The weight-loss treatment showed 22% more loss than a placebo by week 33 with no plateau.
    • Viking Therapeutics stock slipped 1.86% while holding above a key support level of $32.11.

    What to watch next

    • Full peer-reviewed data release from the VK2735 maintenance study
    • Regulatory filing updates for the VK2735 clinical pipeline
    • Comparative efficacy trials against Eli Lilly and Novo Nordisk products
    Sources used for this update (9)
    1. Investor's Business Daily β€” Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
    2. Seeking Alpha β€” Viking Therapeutics stock soars on obesity data (VKTX:NASDAQ)
    3. Barron's β€” Viking Therapeutics Stock Surges 36% After Weight-Loss Drug Trial
    4. careplusvn.com β€” Viking Therapeutics (VKTX) Slips 1.86% as Stock Holds Above Key Support at $32.11 - Trend Following Picks
    5. Stock Titan β€” A weight-loss treatment showed 22% more loss than a placebo by week 33. No plateau was seen.
    6. Yahoo Finance β€” Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing
    7. PR Newswire β€” Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
    8. Yahoo Finance β€” Viking shares surge on updated obesity drug data
    9. endpoints.news β€” Viking touts once-a-month maintenance data for its weight loss candidate
    confidence 90%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community